ArriVent BioPharma (AVBP) Other Accumulated Expenses (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Other Accumulated Expenses data on file, last reported at $39000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 75.78% year-over-year to $39000.0; the trailing twelve-month figure through Mar 2026 stood at $39000.0 (down 75.78% YoY), and the FY2025 full-year result was $18000.0, down 73.13% from the prior year.
• Other Accumulated Expenses improved to $39000.0 in Q1 2026, from $18000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $161000.0 in Q1 2025 to a low of $18000.0 in Q4 2025.
• A 4-year average of $90200.0 and a median of $86000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 335.14% in 2025 and plunged 75.78% in 2026, its largest moves.
• Tracing AVBP's Other Accumulated Expenses over 4 years: stood at $62000.0 in 2023, then grew by 8.06% to $67000.0 in 2024, then slumped by 73.13% to $18000.0 in 2025, then soared by 116.67% to $39000.0 in 2026.
• Business Quant data shows AVBP's Other Accumulated Expenses at $39000.0 in Q1 2026, $18000.0 in Q4 2025, and $105000.0 in Q3 2025.